Physician profile
Lisa A Klock
NPI 1891707832
$8,969.11
in general payments reported to CMS, 2019-2025
47 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,488 · 2020: $635 · 2021: $958 · 2022: $699 · 2023: $1,571 · 2024: $1,720 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,075 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,075.28 |
| Education | $114.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,743.00 | 2019-2025 | |
| Pfizer INC. | $1,309.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $951.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.38 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $443.50 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $408.99 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $363.24 | 2021-2025 | |
| Amgen INC. | $314.37 | 2019-2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $281.99 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Novo Nordisk INC | $271.95 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Allergan, INC. | $249.70 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.04 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $240.21 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $236.52 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $187.19 | 2019-2025 | Trintellix |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Klock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.